1. India Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Coral Laboratories Limited

Coral Laboratories Limited

BBSE:CORALAB
506.95
INR
-7.30
(-1.42%)
53.76EPS
11.72P/E
2.25BMarket Cap
Coral Laboratories Limited
BSE:CORALAB
(Bombay Stock Exchange)

Recent

price

506.95

P/E

ratio

11.72

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
91.53
111.86
116.18
142.2
166.32
205.68
255.63
251.57
247.15
191.04
266.49
204.96
218.03
229.8
316.8
236.18
270.66
Revenue per Share
11.65
15.81
16.87
22.02
26.79
34.7
45.61
34.84
28.6
19.96
37.94
25.32
18.04
44.19
67.61
45.85
53.76
Basic EPS, GAAP
8.62
7.1
-0.88
2.32
-3.85
11.64
24.53
24.45
-10.35
-14.67
-1.2
1.5
30.01
-18.07
-11.66
-22.16
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
3.61
6.02
2.41
2.41
- -
- -
- -
- -
2
1.5
- -
Dividend per Share
92.69
106.76
121.89
141.57
165.35
196.44
305.54
325.63
318.45
323.77
382.48
436.81
433.29
496.83
563.19
585.33
- -
Book Value per Share
92.69
106.62
121.78
141.49
165.29
196.33
305.3
325.43
318.28
323.65
382.4
436.75
433.24
496.65
563
585.17
- -
Tangible Book Value per Share
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
Basic Weighted Avg Shares
327
400
415
508
594
735
913
899
883
683
952
732
779
821
1,132
844
967
Sales/Revenue/Turnover
16.35
15.6
15.14
17.28
16.46
20.07
23.84
15.34
11.92
5.01
14.56
8.5
2.09
17.37
21.75
15.65
16.73
Operating Margin (%)
13
13
13
12
26
17
16
16
19
20
20
20
22
20
20
21
23
Depreciation Expense
42
56
60
79
96
124
163
124
102
71
136
90
64
158
242
164
192
Net Income, GAAP
20.7
20.24
20.37
20.69
21.62
28.76
33.66
31.05
34.11
21.79
23.04
23.7
21.65
23.84
25.61
29.13
27.08
Effective Tax Rate (%)
12.73
14.13
14.52
15.49
16.11
16.87
17.84
13.85
11.57
10.45
14.24
12.35
8.27
19.23
21.34
19.41
19.86
Profit Margin (%)
93
147
206
287
381
466
550
521
656
707
1,011
1,053
1,117
1,290
1,516
1,497
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
LT Debt
331
381
435
506
591
702
1,092
1,163
1,138
1,157
1,366
1,561
1,548
1,775
2,012
2,091
- -
Total Equity
12.9
13.96
12.18
14.68
13.78
16.04
15.61
8.29
5.95
2.24
7.88
3.47
0.8
6.21
8.68
4.29
- -
Return on Invested Capital (%)
12.9
15.93
14.66
16.59
17.24
19.02
17.94
10.87
8.77
6.06
10.27
6
4.24
9.5
12.68
7.89
- -
Return on Capital (%)
13.28
15.85
14.76
16.72
17.46
19.18
18.17
11.04
8.88
6.22
10.74
6.18
4.15
9.5
12.76
7.98
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
43
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4
4
4
Market Capitalization
1,567
1,324
2,251

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
1,770
- -
Cash, Cash Equivalents & STI
- -
307
- -
Accounts Receivable, Net
- -
294
- -
Inventories
- -
205
- -
Total Current Liabilities
- -
273
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
43
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.51%
9.07%
3.93%
Free Cash Flow
148.97%
314.36%
89.96%
Net Income, GAAP
15.36%
20.75%
-32.18%
Sales/Revenue/Turnover
3.88%
0.22%
-25.45%
Total Cash Common Dividend
- -
- -
-25%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
317
322
230
281
1,132
2026
188
190
216
265
844
2027
296
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
24.64
17.86
17.2
7.91
67.61
2026
7.18
16.29
7.77
14.62
45.85
2027
15.08
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
2
2026
- -
- -
- -
- -
1.5
2027
- -
- -
- -
- -
- -
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Coral Laboratories Limited is a pharmaceutical and healthcare company engaged in the manufacturing, marketing, and distribution of a diverse range of pharmaceutical formulations, active pharmaceutical ingredients (APIs), herbal products, and nutraceuticals. Its core products include prescription medicines, generic drugs, over-the-counter (OTC) healthcare products, and herbal supplements. The company operates primarily in India, serving domestic markets as well as select international markets. Founded in 1984 and headquartered in Mumbai, India, Coral Laboratories delivers comprehensive healthcare solutions encompassing cardiovascular, anti-infective, gastrointestinal, and respiratory therapeutic segments. The company manufactures branded and generic formulations across various dosage forms such as tablets, capsules, injectables, and syrups. Additionally, it offers contract manufacturing services and exports its products to multiple countries. Recent company developments within the last 1-2 years include strategic partnerships aimed at expanding product reach and capital infusion for growth initiatives. Coral Laboratories has undertaken efforts to strengthen its portfolio by launching new products in specialty therapeutic areas and enhancing production capabilities with modernized manufacturing facilities. These moves reflect a strategic focus on expanding domestic market share and exploring international business opportunities. Coral Laboratories operates within the pharmaceutical industry, targeting healthcare providers, pharmacies, hospitals, and wellness retailers. The company maintains a network of subsidiaries and collaborations to support research, development, and marketing efforts. As a listed entity on the Bombay Stock Exchange (ticker: CORALAB.BO), Coral Laboratories emphasizes adherence to regulatory standards and quality compliance in all its operations.